Summary

Report Details

The Rare Diseases Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Advancements in R&D and Regulatory Incentives Driving Market Growth

The rare diseases market is driven by a convergence of factors that collectively shape its growth trajectory and impact. One pivotal driver is the increasing awareness and understanding of rare diseases among healthcare professionals, policymakers, and the general public. This heightened awareness leads to earlier diagnosis, improved access to treatment, and expanded support networks for patients and families.

Advancements in research and development, fuelled by both public and private investment, continuously expand the therapeutic landscape for rare diseases. Breakthroughs in areas such as gene therapy, precision medicine, and orphan drug development hold promise for addressing previously unmet medical needs.

Regulatory incentives and policies that encourage innovation and investment play a significant role in driving the rare diseases market forward. These include extended market exclusivity, expedited review processes, and financial incentives for drug development. Furthermore, the globalization of healthcare and the emergence of new markets, particularly in developing countries, present opportunities for market expansion and access to rare disease treatments. Collectively, these driving factors underscore the dynamic and multifaceted nature of the rare diseases market, fuelled by a commitment to improving outcomes for patients facing these challenging conditions.

High Entry Barriers Likely to Challenge Industry Growth

High entry barriers pose a significant challenge to the growth of the rare diseases market. The substantial costs and lengthy timelines associated with research and development deter new entrants, limiting competition and innovation. Additionally, stringent regulatory requirements and complex reimbursement processes further hinder market entry for potential therapies. These barriers create a formidable challenge for companies seeking to develop and commercialize treatments for rare diseases, constraining market growth and potentially limiting patient access to new therapies.

What Questions Should You Ask before Buying a Market Research Report?

• How is the rare diseases market evolving?
• What is driving and restraining the rare diseases market?
• How will each rare diseases submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each rare diseases submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading rare diseases markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the rare diseases projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of rare diseases projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the rare diseases market?
  Where is the rare diseases market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the rare diseases market today, and over the next 10 years:

• Our 344-page report provides 126 tables, 185 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising rare diseases prices and recent developments.

Segments Covered in the Report

Diseases

• Cancer
• Metabolic Diseases
• Neurological Conditions
• Hematologic Disorders
• Infectious Diseases
• Musculoskeletal Disorders
• Cardiovascular Disorders
• Others

Type

• Non Biologics
• Biologics

End-users

• Specialty Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Age Group

• Adult
• Pediatric

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Netherlands
• Switzerland
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Malaysia
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Rare Diseases Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

• AbbVie Inc.
• Alexion Pharmaceuticals, Inc. (AstraZeneca)
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• Biogen Inc.
• Bristol-Myers Squibb Company
• Chiesi Farmaceutici S.p.A.
• Dr. Reddy’s Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Merck & Co Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Incorporated

Overall world revenue for Rare Diseases Market, 2024 to 2034 in terms of value the market will surpass US$200.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Rare Diseases Market, 2024 to 2034 report help you?

In summary, our 340+ page report provides you with the following knowledge:

• Revenue forecasts to 2034 for Rare Diseases Market, 2024 to 2034, with forecasts for disease, type, end-users, and age group each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 25 key national markets – See forecasts for the Rare Diseases Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 17 of the major companies involved in the Rare Diseases Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Rare Diseases Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Rare Diseases Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Increasing Number of Drug Approvals
3.3.1.2 Robust Pipeline by Major Players
3.3.1.3 Increasing Awareness Regarding Rare Diseases
3.3.2 Market Restraining Factors
3.3.2.1 High Research and Development Cost
3.3.2.2 High Entry Barriers to Challenge Market Growth
3.3.2.3 Limited Patient Population
3.3.3 Market Opportunities
3.3.3.1 Increasing Demand from Emerging Economies
3.3.3.2 Increasing Government Support
3.3.3.3 Advancement in Research and Development
3.4 Regulatory Framework
3.5 Emerging Markets and Megatrends
3.6 Porter’s Five Forces Analysis
3.6.1 Bargaining Power of Suppliers
3.6.2 Bargaining Power of Buyers
3.6.3 Competitive Rivalry
3.6.4 Threat from Substitutes
3.6.5 Threat of New Entrants
3.7 PEST Analysis
3.7.1 Political
3.7.2 Economical
3.7.3 Social
3.7.4 Technological
3.8 Pipeline Analysis

4 Rare Diseases Market Analysis by Disease
4.1 Key Findings
4.2 Disease Segment: Market Attractiveness Index
4.3 Rare Diseases Market Size Estimation and Forecast by Disease
4.4 Cancer
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Metabolic Diseases
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Neurological Conditions
4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
4.6.2 Market Share by Region, 2024 & 2034 (%)
4.7 Hematological Disorders
4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
4.7.2 Market Share by Region, 2024 & 2034 (%)
4.8 Infectious Diseases
4.8.1 Market Size by Region, 2024-2034 (US$ Billion)
4.8.2 Market Share by Region, 2024 & 2034 (%)
4.9 Musculoskeletal Disorders
4.9.1 Market Size by Region, 2024-2034 (US$ Billion)
4.9.2 Market Share by Region, 2024 & 2034 (%)
4.10 Cardiovascular Disorders
4.10.1 Market Size by Region, 2024-2034 (US$ Billion)
4.10.2 Market Share by Region, 2024 & 2034 (%)
4.11 Others
4.11.1 Market Size by Region, 2024-2034 (US$ Billion)
4.11.2 Market Share by Region, 2024 & 2034 (%)

5 Rare Diseases Market Analysis by Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 Rare Diseases Market Size Estimation and Forecast by Type
5.4 Non Biologics
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Biologics
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)

6 Rare Diseases Market Analysis by End-users
6.1 Key Findings
6.2 End-users Segment: Market Attractiveness Index
6.4 Rare Diseases Market Size Estimation and Forecast by End-users
6.5 Specialty Pharmacies
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Hospital Pharmacies
6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Retail Pharmacies
6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
6.7.2 Market Share by Region, 2024 & 2034 (%)

7 Rare Diseases Market Analysis by Age Group
7.1 Key Findings
7.2 Age Group Segment: Market Attractiveness Index
7.4 Rare Diseases Market Size Estimation and Forecast by Age Group
7.5 Adult
7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Pediatric
7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
7.6.2 Market Share by Region, 2024 & 2034 (%)

8 Rare Diseases Market Analysis by Region
8.1 Key Findings
8.3 Regional Market Size Estimation and Forecast

9 North America Rare Diseases Market Analysis
9.1 Key Findings
9.2 North America Rare Diseases Market Attractiveness Index
9.3 North America Rare Diseases Market by Country, 2024, 2029 & 2034 (US$ Billion)
9.4 North America Rare Diseases Market Size Estimation and Forecast by Country
9.5 North America Rare Diseases Market Size Estimation and Forecast by Disease
9.6 North America Rare Diseases Market Size Estimation and Forecast by Type
9.7 North America Rare Diseases Market Size Estimation and Forecast by End-users
9.8 North America Rare Diseases Market Size Estimation and Forecast by Age Group
9.9 U.S. Rare Diseases Market Analysis
9.10 Canada Rare Diseases Market Analysis

10 Europe Rare Diseases Market Analysis
10.1 Key Findings
10.2 Europe Rare Diseases Market Attractiveness Index
10.3 Europe Rare Diseases Market by Country, 2024, 2029 & 2034 (US$ Billion)
10.4 Europe Rare Diseases Market Size Estimation and Forecast by Country
10.5 Europe Rare Diseases Market Size Estimation and Forecast by Disease
10.6 Europe Rare Diseases Market Size Estimation and Forecast by Type
10.7 Europe Rare Diseases Market Size Estimation and Forecast by End-users
10.8 Europe Rare Diseases Market Size Estimation and Forecast by Age Group
10.9 Germany Rare Diseases Market Analysis
10.10 UK Rare Diseases Market Analysis
10.11 France Rare Diseases Market Analysis
10.12 Italy Rare Diseases Market Analysis
10.13 Spain Rare Diseases Market Analysis
10.14 Netherlands Rare Diseases Market Analysis
10.15 Switzerland Rare Diseases Market Analysis
10.16 Rest of Europe Rare Diseases Market Analysis

11 Asia Pacific Rare Diseases Market Analysis
11.1 Key Findings
11.2 Asia Pacific Rare Diseases Market Attractiveness Index
11.3 Asia Pacific Rare Diseases Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 Asia Pacific Rare Diseases Market Size Estimation and Forecast by Country
11.5 Asia Pacific Rare Diseases Market Size Estimation and Forecast by Disease
11.6 Asia Pacific Rare Diseases Market Size Estimation and Forecast by Type
11.7 Asia Pacific Rare Diseases Market Size Estimation and Forecast by End-users
11.8 Asia Pacific Rare Diseases Market Size Estimation and Forecast by Age Group
11.9 Japan Rare Diseases Market Analysis
11.10 China Rare Diseases Market Analysis
11.11 India Rare Diseases Market Analysis
11.12 Australia Rare Diseases Market Analysis
11.13 South Korea Rare Diseases Market Analysis
11.14 Malaysia Rare Diseases Market Analysis
11.15 Singapore Rare Diseases Market Analysis
11.16 Rest of Asia Pacific Rare Diseases Market Analysis

12 Latin America Rare Diseases Market Analysis
12.1 Key Findings
12.2 Latin America Rare Diseases Market Attractiveness Index
12.3 Latin America Rare Diseases Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 Latin America Rare Diseases Market Size Estimation and Forecast by Country
12.5 Latin America Rare Diseases Market Size Estimation and Forecast by Disease
12.6 Latin America Rare Diseases Market Size Estimation and Forecast by Type
12.7 Latin America Rare Diseases Market Size Estimation and Forecast by End-users
12.8 Latin America Rare Diseases Market Size Estimation and Forecast by Age Group
12.9 Brazil Rare Diseases Market Analysis
12.10 Mexico Rare Diseases Market Analysis
12.11 Argentina Rare Diseases Market Analysis
12.12 Rest of Latin America Rare Diseases Market Analysis

13 MEA Rare Diseases Market Analysis
13.1 Key Findings
13.2 MEA Rare Diseases Market Attractiveness Index
13.3 MEA Rare Diseases Market by Country, 2024, 2029 & 2034 (US$ Billion)
13.4 MEA Rare Diseases Market Size Estimation and Forecast by Country
13.5 MEA Rare Diseases Market Size Estimation and Forecast by Disease
13.6 MEA Rare Diseases Market Size Estimation and Forecast by Type
13.7 MEA Rare Diseases Market Size Estimation and Forecast by End-users
13.8 MEA Rare Diseases Market Size Estimation and Forecast by Age Group
13.9 GCC Rare Diseases Market Analysis
13.10 South Africa Rare Diseases Market Analysis
13.11 Rest of MEA Rare Diseases Market Analysis

14 Company Profiles
14.1 Competitive Landscape, 2023
14.2 Novartis AG
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.3.1 Net Revenue, 2019-2023
14.2.3.2 Regional Market Shares, 2023
14.2.3.3 R&D Expense, 2019-2023
14.2.5 Product Benchmarking
14.2.6 Strategic Outlook
14.3 Teva Pharmaceutical Industries Ltd.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Revenue, 2019-2023
14.3.3.2 Regional Market Shares, 2023
14.3.3.3 R&D Expense, 2019-2023
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 AbbVie Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Revenue, 2019-2023
14.4.3.2 Regional Market Shares, 2023
14.4.3.3 R&D Expense, 2019-2023
14.4.4 Product Benchmarking
14.5 Alexion Pharmaceuticals, Inc. (AstraZeneca)
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Product Benchmarking
14.5.4 Strategic Outlook
14.6 Amgen Inc.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2019-2023
14.6.3.2 Regional Market Shares, 2023
14.6.3.3 R&D Expense, 2019-2023
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Biogen Inc.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Revenue, 2019-2023
14.7.3.2 Regional Market Shares, 2023
14.7.3.3 R&D Expense, 2019-2023
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 F. Hoffmann-La Roche Ltd.
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Revenue, 2019-2023
14.8.3.2 Regional Market Shares, 2023
14.8.3.3 R&D Expense, 2019-2023
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Johnson & Johnson Services, Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Revenue, 2019-2023
14.9.3.2 Regional Market Shares, 2023
14.9.3.3 R&D Expense, 2019-2023
14.9.5 Product Benchmarking
14.9.6 Strategic Outlook
14.10 Merck & Co Inc.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Revenue, 2019-2023
14.10.3.2 Regional Market Shares, 2023
14.10.3.3 R&D Expense, 2019-2023
14.10.5 Product Benchmarking
14.11 Pfizer Inc.
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Revenue, 2019-2023
14.11.3.2 Regional Market Shares, 2023
14.11.3.3 R&D Expense, 2019-2023
14.11.5 Product Benchmarking
14.11.6 Strategic Outlook
14.12 Sanofi
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Revenue, 2019-2023
14.12.3.2 Regional Market Shares, 2023
14.12.3.3 R&D Expense, 2019-2023
14.12.5 Product Benchmarking
14.13 Takeda Pharmaceutical Company Limited.
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Revenue, 2019-2023
14.13.3.2 R&D Expense, 2018-2022
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
14.14 Bristol-Myers Squibb Company
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Financial Analysis
14.14.3.1 Revenue, 2019-2023
14.14.3.2 Regional Market Shares, 2023
14.14.3.3 R&D Expense, 2019-2023
14.14.4 Product Benchmarking
14.14.5 Strategic Outlook
14.15 Amneal Pharmaceuticals LLC
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Revenue, 2018-2022
14.15.3.2 R&D Expense, 2018-2022
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Dr. Reddy’s Laboratories Ltd.
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.3.1 Revenue, 2019-2023
14.16.3.2 Regional Market Shares, 2022
14.16.3.3 R&D Expense, 2018-2022
14.16.4 Product Benchmarking
14.16.5 Strategic Outlook
14.17 Chiesi Farmaceutici S.p.A.
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Product Benchmarking
14.17.4 Strategic Outlook
14.18 Vertex Pharmaceuticals Incorporated
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Financial Analysis
14.18.3.1 Revenue, 2019-2023
14.18.3.2 Regional Market Shares, 2023
14.18.3.3 R&D Expense, 2019-2023
14.18.4 Product Benchmarking
14.18.5 Strategic Outlook

15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1 Rare Diseases Market Snapshot, 2024 & 2034 (US$ billion, CAGR %)
Table 1 Pfizer Rare Disease Pipeline
Table 2 Sanofi Rare Disease Pipeline
Table 3 Key Factors Affecting the Bargaining Power of Buyer
Table 4 Key Factors Affecting the Bargaining Power of Suppliers
Table 5 Key Factors Affecting the Industry Rivalry
Table 6 Key Factors Affecting the Threat of Substitutes
Table 7 Key Factors Affecting the Threat of New Entrants
Table 8 Pipeline Analysis
Table 9 Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 10 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 11 Metabolic Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 12 Neurological Conditions Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 13 Hematological Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 14 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 15 Musculoskeletal Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 16 Cardiovascular Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 17 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 18 Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 19 Non Biologics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 20 Biologics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 21 Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 22 Specialty Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 23 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 24 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 25 Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 26 Adult Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 27 Pediatric Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 28 Rare Diseases Market Forecast by Region 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 29 North America Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 30 North America Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 31 North America Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 32 North America Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 33 North America Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 34 U.S. Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 35 Canada Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 36 Europe Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 37 Europe Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 38 Europe Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 39 Europe Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 40 Europe Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 41 Germany Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 42 UK Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 43 France Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 44 Italy Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 45 Spain Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 46 Netherlands Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 47 Switzerland Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 48 Rest of Europe Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 49 Asia Pacific Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 50 Asia Pacific Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 51 Asia Pacific Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 52 Asia Pacific Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 53 Asia Pacific Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 54 Japan Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 55 China Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 56 India Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 57 Australia Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 58 South Korea Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 59 Malaysia Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 60 Singapore Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 61 Rest of Asia-Pacific Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 62 Latin America Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 63 Latin America Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 64 Latin America Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 65 Latin America Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 66 Latin America Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 67 Brazil Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 68 Mexico Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 69 Argentina Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 70 Rest of Latin America Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 71 MEA Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 72 MEA Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 73 MEA Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 74 MEA Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 75 MEA Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 76 GCC Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 77 South Africa Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 78 Rest of MEA Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 79 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 80 Novartis AG: Product Benchmarking
Table 81 Novartis AG: Strategic Outlook
Table 82 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 84 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 85 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 AbbVie Inc.: Product Benchmarking
Table 87 Alexion Pharmaceuticals, Inc. (AstraZeneca): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Alexion Pharmaceuticals, Inc. (AstraZeneca): Product Benchmarking
Table 89 Alexion Pharmaceuticals, Inc. (AstraZeneca): Strategic Outlook
Table 90 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Amgen Inc.: Product Benchmarking
Table 92 Amgen Inc.: Strategic Outlook
Table 93 Biogen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Biogen Inc.: Product Benchmarking
Table 95 Biogen Inc.: Strategic Outlook
Table 96 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 F. Hoffmann-La Roche Ltd.: Product Benchmarking
Table 98 F. Hoffmann-La Roche Ltd.: Strategic Outlook
Table 99 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Johnson & Johnson Services, Inc.: Product Benchmarking
Table 101 Johnson & Johnson Services, Inc.: Strategic Outlook
Table 102 Merck & Co Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Merck & Co Inc.: Product Benchmarking
Table 104 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Pfizer Inc.: Product Benchmarking
Table 106 Pfizer Inc.: Strategic Outlook
Table 107 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Sanofi: Product Benchmarking
Table 109 Takeda Pharmaceutical Company Limited.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Takeda Pharmaceutical Company Limited.: Product Benchmarking
Table 111 Takeda Pharmaceutical Company Limited.: Strategic Outlook
Table 112 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Bristol-Myers Squibb Company: Product Benchmarking
Table 114 Bristol-Myers Squibb Company: Strategic Outlook
Table 115 Amneal Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Amneal Pharmaceuticals LLC: Product Benchmarking
Table 117 Amneal Pharmaceuticals LLC: Strategic Outlook
Table 118 Dr. Reddy’s Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 Dr. Reddy’s Laboratories Ltd.: Product Benchmarking
Table 120 Dr. Reddy’s Laboratories Ltd.: Strategic Outlook
Table 121 Amryt Pharma plc: Key Details, (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Amryt Pharma plc: Product Benchmarking
Table 123 Amryt Pharma plc: Strategic Outlook
Table 124 Vertex Pharmaceuticals Incorporated: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 Vertex Pharmaceuticals Incorporated: Product Benchmarking
Table 126 Vertex Pharmaceuticals Incorporated: Strategic Outlook
 
List of Figures
Figure 1 Rare Diseases Market Segmentation
Figure 2 Rare Diseases Market by Disease: Market Attractiveness Index
Figure 3 Rare Diseases Market Forecast by Type: Market Attractiveness Index
Figure 4 Rare Diseases Market Forecast by End-users: Market Attractiveness Index
Figure 5 Rare Diseases Market Forecast by Age Group: Market Attractiveness Index
Figure 6 Rare Diseases Market Attractiveness Index by Region
Figure 7 Global Rare Diseases Market: Market Dynamics
Figure 8 Rare Diseases Market: Impact Analysis
Figure 9 CDER’s Annual Novel Drug Approvals: 2014 – 2023
Figure 10 Rare Diseases Market: Porter’s Five Forces Analysis
Figure 11 Rare Diseases Market: PEST Analysis
Figure 12 Rare Diseases Market Forecast by Type: Market Attractiveness Index
Figure 13 Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion)
Figure 14 Rare Diseases Market Share Forecast by Disease, 2024, 2029, 2034 (%)
Figure 15 Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 16 Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 17 Metabolic Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 18 Metabolic Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 19 Neurological Conditions Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 20 Neurological Conditions Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Hematological Disorders Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 22 Hematological Disorders Market Share Forecast by Region, 2024 & 2034 (%)
Figure 23 Infectious Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 24 Infectious Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Musculoskeletal Disorders Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 26 Musculoskeletal Disorders Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Cardiovascular Disorders Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 28 Cardiovascular Disorders Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 30 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Rare Diseases Market Forecast by Type: Market Attractiveness Index
Figure 32 Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 33 Rare Diseases Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 34 Non Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 35 Non Biologics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 36 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 37 Biologics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 38 Rare Diseases Market Forecast by End-users: Market Attractiveness Index
Figure 39 Rare Diseases Market Forecast By End-users, 2024-2034 (US$ Billion)
Figure 40 Rare Diseases Market Share Forecast by End-users, 2024, 2029, 2034 (%)
Figure 41 Specialty Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 42 Specialty Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 44 Hospital Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 45 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 46 Retail Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 47 Rare Diseases Market Forecast by Age Group: Market Attractiveness Index
Figure 48 Rare Diseases Market Forecast By Age Group, 2024-2034 (US$ Billion)
Figure 49 Rare Diseases Market Share Forecast by Age Group, 2024, 2029, 2034 (%)
Figure 50 Adult Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 51 Adult Market Share Forecast by Region, 2024 & 2034 (%)
Figure 52 Pediatric Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 53 Pediatric Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 Rare Diseases Market Forecast by Region, 2024 & 2034 (Revenue, CAGR%)
Figure 55 Rare Diseases Market Share Forecast by Region 2024, 2029, 2034(%)
Figure 56 Rare Diseases Market by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Figure 57 North America Rare Diseases Market Attractiveness Index
Figure 58 North America Rare Diseases Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 59 North America Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 60 North America Rare Diseases Market Share Forecast by Country, 2024 & 2034 (%)
Figure 61 North America Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion)
Figure 62 North America Rare Diseases Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 63 North America Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 64 North America Rare Diseases Market Share Forecast by Type, 2024 & 2034 (%)
Figure 65 North America Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 66 North America Rare Diseases Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 67 North America Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion)
Figure 68 North America Rare Diseases Market Share Forecast by Age Group, 2024 & 2034 (%)
Figure 69 U.S. Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 70 Canada Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 71 Europe Rare Diseases Market Attractiveness Index
Figure 72 Europe Rare Diseases Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 73 Europe Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 74 Europe Rare Diseases Market Share Forecast by Country, 2024 & 2034 (%)
Figure 75 Europe Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion)
Figure 76 Europe Rare Diseases Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 77 Europe Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 78 Europe Rare Diseases Market Share Forecast by Type, 2024 & 2034 (%)
Figure 79 Europe Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 80 Europe Rare Diseases Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 81 Europe Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion)
Figure 82 Europe Rare Diseases Market Share Forecast by Age Group, 2024 & 2034 (%)
Figure 83 Germany Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 84 U.K. Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 85 France Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 86 Italy Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 87 Spain Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 88 Netherland Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 89 Switzerland Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 90 Rest of Europe Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 91 Asia Pacific Rare Diseases Market Attractiveness Index
Figure 92 Asia Pacific Rare Diseases Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 93 Asia Pacific Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 94 Asia Pacific Rare Diseases Market Share Forecast by Country, 2024 & 2034 (%)
Figure 95 Asia Pacific Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion)
Figure 96 Asia Pacific Rare Diseases Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 97 Asia Pacific Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 98 Asia Pacific Rare Diseases Market Share Forecast by Type, 2024 & 2034 (%)
Figure 99 Asia Pacific Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 100 Asia Pacific Rare Diseases Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 101 Asia Pacific Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion)
Figure 102 Asia Pacific Rare Diseases Market Share Forecast by Age Group, 2024 & 2034 (%)
Figure 103 Japan Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 104 China Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 105 India Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 106 Australia Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 107 South Korea Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 108 Malaysia Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 109 Singapore Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 110 Rest of Asia Pacific Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 111 Latin America Rare Diseases Market Attractiveness Index
Figure 112 Latin America Rare Diseases Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 113 Latin America Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 114 Latin America Rare Diseases Market Share Forecast by Country, 2024 & 2034 (%)
Figure 115 Latin America Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion)
Figure 116 Latin America Rare Diseases Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 117 Latin America Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 118 Latin America Rare Diseases Market Share Forecast by Type, 2024 & 2034 (%)
Figure 119 Latin America Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 120 Latin America Rare Diseases Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 121 Latin America Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion)
Figure 122 Latin America Rare Diseases Market Share Forecast by Age Group, 2024 & 2034 (%)
Figure 123 Brazil Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 124 Mexico Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 125 Argentina Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 126 Rest of Latin America Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 127 MEA Rare Diseases Market Attractiveness Index
Figure 128 MEA Rare Diseases Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 129 MEA Rare Diseases Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 130 MEA Rare Diseases Market Share Forecast by Country, 2024 & 2034 (%)
Figure 131 MEA Rare Diseases Market Forecast by Disease, 2024-2034 (US$ Billion)
Figure 132 MEA Rare Diseases Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 133 MEA Rare Diseases Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 134 MEA Rare Diseases Market Share Forecast by Type, 2024 & 2034 (%)
Figure 135 MEA Rare Diseases Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 136 MEA Rare Diseases Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 137 MEA Rare Diseases Market Forecast by Age Group, 2024-2034 (US$ Billion)
Figure 138 MEA Rare Diseases Market Share Forecast by Age Group, 2024 & 2034 (%)
Figure 139 GCC Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 140 South Africa Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 141 Rest of MEA Rare Diseases Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 142 Rare Diseases Market: Company Share Analysis, 2023
Figure 143 Novartis AG: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 144 Novartis AG: Regional Market Shares, 2023
Figure 145 Novartis AG: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 146 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2019-2023 (US$ million, AGR%)
Figure 147 Teva Pharmaceutical Industries Ltd: Regional Market Shares, 2023
Figure 148 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 149 AbbVie Inc.: Annual Revenue, 2019-2023 (US$ Million, AGR%)
Figure 150 AbbVie Inc.: Regional Market Shares, 2023
Figure 151 AbbVie Inc.: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 152 Amgen Inc.: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 153 Amgen Inc.: Regional Market Shares, 2023
Figure 154 Amgen Inc.: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 155 Biogen Inc.: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 156 Biogen Inc.: Regional Market Shares, 2023
Figure 157 Biogen Inc.: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 158 F. Hoffmann-La Roche Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 159 F. Hoffmann-La Roche Ltd.: Regional Market Shares, 202
Figure 160 F. Hoffmann-La Roche Ltd.: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 161 Johnson & Johnson Services, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 162 Johnson & Johnson Services, Inc.: Regional Market Shares, 2023
Figure 163 Johnson & Johnson Services, Inc.: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 164 Merck & Co Inc.: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 165 Merck & Co Inc.: Regional Market Shares, 2023
Figure 166 Merck & Co Inc.: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 167 Pfizer Inc.: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 168 Pfizer Inc.: Regional Market Shares, 2023
Figure 169 Pfizer Inc.: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 170 Sanofi: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 171 Sanofi: Regional Market Shares, 2023
Figure 172 Sanofi: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 173 Takeda Pharmaceutical Company Limited.: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 174 Takeda Pharmaceutical Company Limited.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 175 Bristol-Myers Squibb Company: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 176 Bristol-Myers Squibb Company: Regional Market Shares, 2023
Figure 177 Bristol-Myers Squibb Company: R&D Expense, 2019-2023 (US$ Million, AGR%)
Figure 178 Amneal Pharmaceuticals LLC: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 179 Amneal Pharmaceuticals LLC: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 180 Dr. Reddy’s Laboratories Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 181 Dr. Reddy’s Laboratories Ltd.: Regional Market Shares, 2022
Figure 182 Dr. Reddy’s Laboratories Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 183 Vertex Pharmaceuticals Incorporated: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 184 Vertex Pharmaceuticals Incorporated: Regional Market Shares, 2023
Figure 185 Vertex Pharmaceuticals Incorporated: R&D Expense, 2019-2023 (US$ Million, AGR%)